Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 20 studies | 69% ± 18% | |
lung | 17 studies | 60% ± 18% | |
intestine | 13 studies | 65% ± 24% | |
kidney | 9 studies | 64% ± 20% | |
brain | 9 studies | 30% ± 15% | |
eye | 7 studies | 39% ± 13% | |
liver | 6 studies | 57% ± 16% | |
uterus | 5 studies | 65% ± 25% | |
prostate | 5 studies | 60% ± 33% | |
lymph node | 5 studies | 80% ± 5% | |
pancreas | 4 studies | 62% ± 29% | |
placenta | 4 studies | 71% ± 19% | |
bone marrow | 4 studies | 49% ± 25% | |
breast | 4 studies | 71% ± 12% | |
heart | 3 studies | 37% ± 16% | |
adipose | 3 studies | 39% ± 24% | |
adrenal gland | 3 studies | 65% ± 13% | |
esophagus | 3 studies | 67% ± 24% | |
skin | 3 studies | 66% ± 17% | |
thymus | 3 studies | 71% ± 34% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 33709.16 | 653 / 653 | 100% | 1410.99 | 605 / 605 |
skin | 100% | 34274.14 | 1809 / 1809 | 100% | 1740.17 | 470 / 472 |
uterus | 100% | 27602.04 | 170 / 170 | 100% | 1267.41 | 457 / 459 |
ovary | 100% | 42202.09 | 180 / 180 | 100% | 1312.83 | 428 / 430 |
stomach | 100% | 30633.12 | 359 / 359 | 99% | 1631.28 | 284 / 286 |
intestine | 100% | 32237.04 | 966 / 966 | 99% | 2000.71 | 523 / 527 |
prostate | 100% | 26834.76 | 245 / 245 | 99% | 2138.01 | 498 / 502 |
adrenal gland | 100% | 36421.65 | 258 / 258 | 99% | 1209.32 | 228 / 230 |
brain | 99% | 17878.69 | 2624 / 2642 | 100% | 906.95 | 703 / 705 |
pancreas | 100% | 31474.90 | 328 / 328 | 99% | 958.65 | 176 / 178 |
kidney | 100% | 32759.44 | 89 / 89 | 99% | 1179.12 | 890 / 901 |
bladder | 100% | 28587.19 | 21 / 21 | 99% | 1562.09 | 497 / 504 |
lung | 100% | 24069.41 | 576 / 578 | 98% | 1075.67 | 1137 / 1155 |
breast | 100% | 30417.75 | 459 / 459 | 97% | 912.66 | 1085 / 1118 |
esophagus | 100% | 31434.01 | 1445 / 1445 | 97% | 751.27 | 177 / 183 |
liver | 85% | 6155.62 | 193 / 226 | 82% | 526.14 | 332 / 406 |
adipose | 100% | 31594.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 3643.20 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 1922.74 | 29 / 29 |
spleen | 100% | 25132.04 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 1382.64 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 1408.57 | 1 / 1 |
blood vessel | 100% | 21290.46 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 26293.25 | 911 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 12249.31 | 834 / 861 | 0% | 0 | 0 / 0 |
muscle | 71% | 5272.79 | 568 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006915 | Biological process | apoptotic process |
GO_1990544 | Biological process | mitochondrial ATP transmembrane transport |
GO_1901029 | Biological process | negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
GO_0140021 | Biological process | mitochondrial ADP transmembrane transport |
GO_0005744 | Cellular component | TIM23 mitochondrial import inner membrane translocase complex |
GO_0016020 | Cellular component | membrane |
GO_0005743 | Cellular component | mitochondrial inner membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005634 | Cellular component | nucleus |
GO_0005471 | Molecular function | ATP:ADP antiporter activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SLC25A6 |
Protein name | ADP/ATP translocase 3 (ADP,ATP carrier protein 3) (ADP,ATP carrier protein, isoform T2) (ANT 2) (Adenine nucleotide translocator 3) (ANT 3) (Solute carrier family 25 member 6) [Cleaved into: ADP/ATP translocase 3, N-terminally processed] ADP/ATP translocase (ADP,ATP carrier protein) |
Synonyms | hCG_1746794 CDABP0051 ANT3 AAC3 |
Description | FUNCTION: ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (By similarity). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By similarity). In addition to its ADP:ATP antiporter activity, also involved in mitochondrial uncoupling and mitochondrial permeability transition pore (mPTP) activity . Plays a role in mitochondrial uncoupling by acting as a proton transporter: proton transport uncouples the proton flows via the electron transport chain and ATP synthase to reduce the efficiency of ATP production and cause mitochondrial thermogenesis (By similarity). Proton transporter activity is inhibited by ADP:ATP antiporter activity, suggesting that SLC25A6/ANT3 acts as a master regulator of mitochondrial energy output by maintaining a delicate balance between ATP production (ADP:ATP antiporter activity) and thermogenesis (proton transporter activity) (By similarity). Proton transporter activity requires free fatty acids as cofactor, but does not transport it (By similarity). Also plays a key role in mPTP opening, a non-specific pore that enables free passage of the mitochondrial membranes to solutes of up to 1.5 kDa, and which contributes to cell death . It is however unclear if SLC25A6/ANT3 constitutes a pore-forming component of mPTP or regulates it (By similarity). . FUNCTION: Catalyzes the exchange of ADP and ATP across the membrane. . |
Accessions | P12236 Q6I9V5 ENST00000711214.1 ENST00000381401.11 |